12/09/2025
For years Tabernanthe Iboga 🌶 root has been used Homeopathicly for Opioid addiction. Now, the military is looking at it for PTSD & TBI treatment whereas it modified the 🧠.
(In the present study (see attached) - reports a prospective observational study of the Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities...)
🧠 Brain scans of individuals treated with ibogaine 🪴, the active alkaloid from the Tabernanthe iboga plant, show significant changes consistent with neuroplasticity and a restoration of normal brain activity.
These changes correlate with clinical improvements in conditions like traumatic brain injury (TBI), PTSD, anxiety, and depression.
🧠 Key findings from neuroimaging studies include:
● Changes in Brain Rhythms: Electroencephalography (EEG) scans show that ibogaine treatment shifts brain activity toward slower, calmer rhythms, making brain signals more predictable. Specifically, an increase in theta rhythms has been observed in patients with improved executive function, which researchers speculate may encourage neuroplasticity and cognitive flexibility.
● Altered Cortical Activity: Veterans with reduced PTSD symptoms after treatment show a reduction in the complexity of brain activity in the cortex, potentially lowering the heightened stress response seen in PTSD.
● Increased Perfusion in Key Regions: In a case study involving a patient with alcohol use disorder, post-treatment SPECT neuroimaging revealed increased blood flow (perfusion) in several brain regions associated with the disorder, including the bilateral caudate nuclei, left putamen, right insula, and temporal, occipital, and cerebellar regions.
● Neuroregenerative Effects: In two case studies of multiple sclerosis (MS) patients, brain scans revealed substantial lesion shrinkage and decreased markers of inflammation, suggesting potential remyelination and reduced inflammation. Both patients exhibited changes in cortical and subcortical regions involved in pain and emotional processing.
● Reversal of Atrophy: In one highly noted case, a 73-year-old veteran and former governor, Rick Perry, had brain atrophy that vanished on a second MRI scan six months after an ibogaine experience, with one neurosurgeon commenting he had "the brain of a 40-year-old".
● Gene Expression and Metabolism: At a molecular level, ibogaine treatment has been shown to upregulate the expression of key neurotrophic factors like Brain-Derived Neurotrophic Factor (BDNF) and Glial Cell Line-Derived Neurotrophic Factor (GDNF), which are involved in neuron growth and survival, as well as enzymes related to energy metabolism, suggesting a fundamental "rewiring" process.
● These imaging and molecular findings suggest that ibogaine facilitates a state of heightened neuroplasticity, allowing the brain to adapt and potentially repair damage from trauma or addiction, though it is important to note that ibogaine can have serious cardiac risks and must be administered under strict medical supervision. ..."
Abstract
"... Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a plant-derived compound known to interact with multiple neurotransmitter systems that has been studied primarily as a treatment for substance use disorders. Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern. In the present study, we report a prospective observational study of the Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities, in 30 male SOVs with predominantly mild TBI. We assessed changes in the World Health Organization Disability Assessment Schedule from baseline to immediately (primary outcome) and 1 month (secondary outcome) after treatment. Additional secondary outcomes included changes in PTSD (Clinician-Administered PTSD Scale for DSM-5), depression (Montgomery–Åsberg Depression Rating Scale) and anxiety (Hamilton Anxiety Rating Scale). MISTIC resulted in significant improvements in functioning both immediately (Pcorrected < 0.001, Cohen’s d = 0.74) and 1 month (Pcorrected < 0.001, d = 2.20) after treatment and in PTSD (Pcorrected < 0.001, d = 2.54), depression (Pcorrected < 0.001, d = 2.80) and anxiety (Pcorrected < 0.001, d = 2.13) at 1 month after treatment. There were no unexpected or serious adverse events. Controlled clinical trials to assess safety and efficacy are needed to validate these initial open-label findings. registration ..."
📜 Navy friend just got back from Mexico where she went for Tabernanthe Iboga 🪴 therapy, to "de-frag" her 🧠 . She just posted the journey on FB.
Now i'm curious, because the attached studies are NOW linking treatment to PTSD & Traumatic Brain Disorders, beyond Opioid addiction treatment.
Amy & I served in PAO together, she has multiple deployments to Iraq 🇮🇶 & Afghanistan 🇦🇫, was a prior Marine E6, before mustang to Navy PAO.
*Sources Various Open Source
https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html
https://www.ucsf.edu/news/2023/05/425246/ibogaine-inspires-new-treatments-addiction-and-depression
https://sunshinebehavioralhealth.com/blog/homeopathic-opiate-treatment/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10878970/
https://www.instagram.com/reel/DIakyGwgD5c/?igsh=Ymw2OWRxZnNtNnA1